IP Library Granted Patent US 7,781,446
Granted Patent B2
US 7,781,446 · App. 11/701,109 · Granted Aug 24, 2010

Use of CCI-779 as an antineoplastic agent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,781,446
App. No.
11/701,109
Granted
Aug 24, 2010
Kind
B2
Abstract

This invention provides the use of CCI-779 in the treatment of neoplasms.

Claims (2)

1. A method of treating a refractory neoplasm in a mammal in need thereof, which comprises providing to said mammal a therapeutically effective amount of CCI-779, wherein said mammal has been previously treated with standard chemotherapy and wherein said refractory neoplasm has progressed following treatment with said standard chemotherapy, wherein said refractory neoplasm is renal cancer.

2. A method of reducing the size of a refractory human renal cell tumor in a human patient, which comprises providing to said human patient a therapeutically effective amount of CCI-779, wherein said human patient has been previously treated with standard chemotherapy and wherein said refractory human renal cell tumor has progressed following treatment with said standard chemotherapy.

Assignments (1)
CHANGE OF NAME Recorded Jun 16, 2010
From: WYETH
To: WYETH LLC
Reel/Frame 024541/0922 →